Discontinued — last reported Q2 '12
Business Segments · Impairment Of Intangible Assets Excluding Goodwill
Pharmaceutical — Impairment Of Intangible Assets Excluding Goodwill
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ2 2012
Last reportedQ2 2012
Rolls up toImpairment Charges
How to read this metric
An increase signals that specific drug pipelines or intellectual property are underperforming or facing competitive threats.
Detailed definition
Measures the reduction in the carrying value of non-goodwill intangible assets, such as patents, trademarks, or acquired...
Peer comparison
A critical metric for pharma companies heavily reliant on patent-protected drug portfolios.
Metric ID:
jnj_segment_pharmaceutical_impairment_of_intangible_assets_excluding_goodwillSimilar Metrics at Other Companies
Frequently Asked Questions
- What does pharmaceutical — impairment of intangible assets excluding goodwill mean?
- The loss in value of intangible assets like patents or licenses due to reduced future earnings potential.